Sandoz, Mylan Slip Teva Patent Suits Over MS Drug Research

Law360, New York (July 16, 2013, 5:05 PM EDT) -- Mylan Pharmaceuticals Inc. and Sandoz Inc. on Tuesday escaped almost identical infringement suits by Teva Pharmaceuticals Ltd. after they agreed to stop using its patented technology in seeking U.S. Food and Drug Administration approval for generic versions of Teva's multiple sclerosis drug Copaxone.

U.S. District Katherine Forrest granted motions to dismiss by Mylan and Sandoz after they told her that they would no longer use certain polypeptide markers to measure the weight of samples of glatiramer acetate, the active ingredient in Copaxone. Teva’s suits accused them...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.